Viridian Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 64 to 73.
Can You Really Time The Stock Market?
IBD's proprietary RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
Over 100 years of market history reveals that the best-performing stocks typically have an RS Rating of above 80 as they launch their largest runs. See if Viridian Therapeutics can continue to rebound and hit that benchmark.
Viridian Therapeutics has risen more than 5% past an 18.27 entry in a first-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% earnings growth last quarter, while sales growth came in at 14%.
The company holds the No. 319 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
